Itolizumab – a humanized anti-CD6 monoclonal antibody with a better side effects profile for the treatment of psoriasis

References

• KandpurSBhariNNewer targeted therapies in psoriasisIndian J Dermatol Venereol Leprol201379Suppl 7S47S5223974694
   PubMed Web of Science ®Google Scholar
• AiraLELópez-RequenaAFuentesDImmunological and histological evaluation of clinical samples from psoriasis patients treated with anti-CD6 itolizumabMAbs20146378379324594862
   PubMed Web of Science ®Google Scholar
• MahajanRHandaSPathophysiology of psoriasisIndian J Dermatol Venereol Leprol201379Suppl 7S1S923974689
   PubMed Web of Science ®Google Scholar
• RaychaudhuriSPNguyenCTRaychaudhuriSKGershwinMEIncidence and nature of infectious disease in patients treated with Anti-TNF agentsAutoimmun Rev200992678119716440
   PubMed Web of Science ®Google Scholar
• StrangfeldAListingJInfections and musculoskeletal conditions: bacterial and opportunistic infections during anti-TNF therapyBest Pract Res Clin Rheumatol20062061181119517127203
   PubMed Web of Science ®Google Scholar
• PallaviciniFBCaporaliRSarzi-PuttiniPTumour necrosis factor antagonist therapy and cancer development: analysis of the LORHEN registryAutoimmun Rev20109317518019647103
   PubMed Web of Science ®Google Scholar
• CoimbraSFigueiredoACastroERocha-PereiraPSantos-SilvaAThe role of cells and cytokines in the pathogenesis of psoriasisInt J Dermatol201251438939522435425
   PubMed Web of Science ®Google Scholar
• StockingerBVeldhoenMDifferentiation and function of Th17T cellsCurr Opin Immunol200719328128617433650
   PubMed Web of Science ®Google Scholar
• Alonso-RamirezRLoiselSBuorsCRationale for targeting CD6 as a treatment for autoimmune diseasesArthritis Epub2102011
   Google Scholar
• GimferrerICalvoMMittelbrunnMRelevance of CD 6-mediated interactions in T cell activation and proliferationJ Immunol20041732262227015294938
   PubMed Web of Science ®Google Scholar
• NestleFOKaplanDHBarkerJPsoriasisN Eng J Med20093615496509
   PubMed Web of Science ®Google Scholar
• Van ParijsLIbraghimovAAbbasAKThe roles of costimulation and Fas in T cell apoptosis and peripheral toleranceImmunity1996433213288624822
   PubMed Web of Science ®Google Scholar
• AlonsoRHuertaVde LeonJTowards the definition of a chimpanzee and human conserved CD6 domain 1 epitope recognized by T1 monoclonal antibodyHybridoma (Larchmt)200827429130118707547
   PubMedGoogle Scholar
• BeckAWurchTReichertJM6th Annual European Antibody Congress 2010: November 29–December 1, 2010, Geneva, SwitzerlandMAbs20113211113221441785
   PubMedGoogle Scholar
• SingerNGFoxDAHaqqiTMCD6: expression during development, apoptosis and selection of human and mouse thymocytesInt Immunol200214658559712039910
   PubMed Web of Science ®Google Scholar
• RodriguezPCTorres-MoyaRReyesGA clinical exploratory study with itolizumab, an anti-CD6 antibody, in patients with rheumatoid arthritisResults Immunol2012220421124371585
   PubMedGoogle Scholar
• BowenMAPatelDDLiXCloning, mapping and characterization of activated leucocyte-cell adhesion molecule (ALCAM), a CD6 ligandJ Exp Med1995181221322207760007
   PubMed Web of Science ®Google Scholar
• Alzumab™ (Itolizumab) solution for iv infusion [prescribing information]IndiaBiocon, Inc2013 Available from: http://www.biocon.com/docs/prescribing_information/immunotherapy/alzumab_pi.pdfAccessed April 3, 2015
   Google Scholar
• Le DantecCAlonsoRFaliTRationale for treating primary Sjögren’s syndrome patients with an anti-CD6 monoclonal antibody (Itolizumab)Immunol Res2013562–334134723576060
   PubMed Web of Science ®Google Scholar
• NairPMelarkodeRRajkumarDMonteroECD6 synergistic co-stimulation promoting proinflammatory response is modulated without interfering with the activated leucocyte cell adhesion molecule interactionClin Exp Immunol201016211613020726988
   PubMed Web of Science ®Google Scholar
• Izquierdo-CanoLEspinosa-EstradaEHernández-PadrónCAnticuerpo monoclonal humanizado itolizumab (anti-cd6) en síndromes linfoproliferativos cd 6+. Experiencia preliminar. [Humanized monoclonal antibody Itolizumab (anti-cd6) in patients with lymphopro-liferative disorders cd6 +. Preliminary experience]Revista Cubana de Hematología, Inmunología y Hemoterapia201430300 Spanish
   Google Scholar
• GimferrerIFarnósMCalvoMThe accessory molecules CD5 and CD6 associate on membrane of lymphoid T cellsJ Biol Chem2003278108564857112473675
   PubMed Web of Science ®Google Scholar
• JayaramanKBiocon’s first-in-class anti-CD6 mAb reaches the marketNat Biotechnol201331121062106324316625
   PubMed Web of Science ®Google Scholar
• Di CesareADi MeglioPNestleFOThe IL-23/Th17 axis in the immunopathogenesis of psoriasisJ Invest Dermatol20091291339135019322214
   PubMed Web of Science ®Google Scholar
• AnandAAssudaniDNairPSafety, efficacy and pharmacokinetics of T1h, a humanized anti-CD6 monoclonal antibody, in moderate to severe chronic plaque psoriasis – results from a randomized phase II trialJ Immunol2010 abstract1849613
   Web of Science ®Google Scholar
• KrupashankarDSDograSKuraMEfficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, phase-III studyJ Am Acad Dermatol201471348449224703722
   PubMed Web of Science ®Google Scholar
• ReichertJMWhich are the antibodies to watch in 2013?MAbs2013511423254906
   PubMed Web of Science ®Google Scholar
• Enbrel^R (Etanercept) [package insert]USAmgen1997 Available from: http://pi.amgen.com/united_states/enbrel/derm/enbrel_pi.pdfAccessed April 3, 2015
   Google Scholar
• ReichKNestleFOPappKInfliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trialLancet20053661367137416226614
   PubMed Web of Science ®Google Scholar
• MenterATyringSKGordonKAdalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trialJ Am Acad Dermatol20045153454215389187
   PubMed Web of Science ®Google Scholar
• LeonardiCLKimballABPappKAPHOENIX 1 study investigatorsEfficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)Lancet20083711665167418486739
   PubMed Web of Science ®Google Scholar
• KoflerDMSeversonCAMousissianNDe JagerPLHaflerDAThe CD6 multiple sclerosis susceptibility allele is associated with alterations in CD4+ T cell proliferationJ Immunol20111873286329121849685
   PubMed Web of Science ®Google Scholar
• EllisCNKruegerGGAlefacept Clinical Study GroupTreatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytesN Engl J Med2001345424825511474662
   PubMed Web of Science ®Google Scholar
• LebwohlMChristophersELangleyROrtonneJPRobertsJGriffithsCEAlefacept Clinical Study GroupAn international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasisArch Dermatol2003139671972712810502
   PubMed Web of Science ®Google Scholar
• GordonKBLangleyRGLeonardiCClinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension studyJ Am Acad Dermatol200655459860617010738
   PubMed Web of Science ®Google Scholar
• GottliebABMathesonRTLoweNAdalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trialJ Am Acad Dermatol200858110611517936411
   PubMed Web of Science ®Google Scholar
• TyringSGordonKBPoulinYLong-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasisArch Dermatol2007143671972617576937
   PubMed Web of Science ®Google Scholar
• LeonardiCLPowersJLMathesonRTEtanercept Psoriasis Study GroupEtanercept as monotherapy in patients with psoriasisN Engl J Med20033492014202214627786
   PubMed Web of Science ®Google Scholar
• GottliebABEvansRLiSInfliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trialJ Am Acad Dermatol200451453454215389187
   PubMed Web of Science ®Google Scholar
• MenterAFeldmanSRWeinsteinGDA randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasisJ Am Acad Dermatol20075631e1e1517097378
   PubMed Web of Science ®Google Scholar
• PappKALangleyRGLebwohlMPHOENIX 2 study investigatorsEfficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)Lancet20083711675168418486740
   PubMed Web of Science ®Google Scholar